All surveyed drug sellers (i.e. pharmacists) in the city of Busan and the province of Gyeongnam indicated a decrease, whether small or large, in outpatient prescriptions following the COVID-19 outbreak in South Korea in early 2020. Around three-quarters said they had seen decreases of between 11 percent and 40 percent. This trend matches that of most other regions in Korea. This decrease is attributed to fewer hospital visits in the midst of the COVID-19 crisis.
Changes in hospital outpatient prescriptions since COVID-19 outbreak in Busan and Gyeongnam in South Korea in 2020
Basic Account
Get to know the platform
You only have access to basic statistics.
This statistic is not included in your account.
Starter Account
The ideal entry-level account for individual users
- Instant access to 1m statistics
- Download in XLS, PDF & PNG format
- Detailed references
$189 USD $149 USD / Month *
in the first 12 months
Professional Account
Full access
Business Solutions including all features.
* Prices do not include sales tax.
Other statistics that may interest you Statistics on
About the industry
10
- Basic Statistic Top challenges for pharmaceutical companies during COVID-19 2020
- Basic Statistic Launch disruption on global pharmaceutical market due to coronavirus 2020-2025
- Premium Statistic Impact of COVID-19 on revenue of hospitality and retail sector South Korea 2020
- Premium Statistic Changes in outpatient prescriptions in Gwangju and Jeolla South Korea 2020
- Premium Statistic Adjusted pharmaceutical sales forecast in South Korea 2020, by drug type
- Premium Statistic Impact of COVID-19 on pharmacy operations in South Korea 2020
- Premium Statistic Changes in outpatient prescriptions in Daegu and Gyeongbuk South Korea 2020
- Premium Statistic Changes in outpatient prescriptions in Daejeon and Chungcheong South Korea 2020
- Premium Statistic Impact of COVID-19 on OTC pharmacy sales South Korea 2020
- Basic Statistic Merck & Co total assets 2009-2022
About the region
10
- Basic Statistic Moderna total assets 2016-2022
- Basic Statistic Moderna net income 2016-2022
- Basic Statistic R&D expenses of Moderna 2016-2022
- Basic Statistic Moderna Inc collaboration revenue by related party 2018-2022
- Basic Statistic R&D expenses of Moderna by type 2022
- Basic Statistic Moderna's revenue 2016-2022
- Basic Statistic Merck & Co. number of employees 2008-2022
- Premium Statistic Pfizer's total revenue 2006-2022
- Basic Statistic AbbVie's total assets 2010-2022
- Premium Statistic AbbVie's revenue by therapy area 2022
Selected statistics
10
- Basic Statistic Sanofi's total assets 2007-2022
- Basic Statistic Merck & Co cash dividends declared 2006-2022
- Premium Statistic Pfizer's revenues in the U.S. and abroad 2009-2022
- Premium Statistic Merck & Co - expenditure on research and development 2006-2022
- Premium Statistic AstraZeneca's expenditure on research and development 2006-2022
- Premium Statistic Sales of Johnson & Johnson 2006-2022 by region
- Basic Statistic GSK's operating profit by division 2006-2021
- Premium Statistic Johnson & Johnson's number of employees 2004-2022
- Premium Statistic Sales of Johnson & Johnson worldwide 2011-2022, by segment
- Premium Statistic Global pharmaceutical pipeline by therapy area 2013-2017
Other regions
10
- Basic Statistic Revenue of leading European pharmaceutical markets 2021
- Basic Statistic YTD stock performance of biopharma companies working on COVID March 2020
- Basic Statistic Output value of life sciences industry California 2022, by sector
- Basic Statistic Pharmaceuticals manufacturing: revenue growth Netherlands 2006-2021
- Basic Statistic Employment at select top pharmaceutical companies in Denmark 2022
- Premium Statistic Italy: number of R&D employees of biotech pharma companies 2014-2017
- Premium Statistic Market size of branded biopharmaceuticals in China 2013-2023
- Basic Statistic Medication sales of the Ipsen Group 2019
- Basic Statistic Top pharmaceutical companies in Sweden 2020, by sales
- Premium Statistic Impact of COVID-19 on inbound tourist arrivals South Korea 2020
Related statistics
10
- Premium Statistic Changes in outpatient prescriptions during COVID-19 in Seoul South Korea 2020
- Premium Statistic Anti-cancer drugs estimated market size in South Korea 2014-2020
- Premium Statistic Anti-diabetics estimated market size in South Korea 2014-2020
- Premium Statistic Cardiovascular disease drugs estimated market size in South Korea 2014-2020
- Premium Statistic Cholesterol drugs estimated market size in South Korea 2014-2020
- Premium Statistic Traditional medicine industry South Korea 2021, by sales revenue
- Premium Statistic Traditional medicine industry sales in South Korea 2021, by sector
- Premium Statistic Sales revenue Yuhan 2015-2022
- Premium Statistic Changes in outpatient prescriptions in Gyeonggi/Incheon/Gangwon South Korea 2020
- Premium Statistic Leading pharmaceutical businesses South Korea 2022, by revenue
Further related statistics
10
- Celgene's revenue and net income 2006-2018
- M&A capacities - changes for the global pharma industry 2008-2015
- Medicinal market growth worldwide including rebates 2009-2018
- Expenditure worldwide on diabetes by market 2013-2018
- AstraZeneca's revenue from top product Pulmicort 2006-2022
- CVS Health's total assets 2005-2022
- Walgreens gross profit and net earnings in the U.S. 2005-2022
- Revenue of Sinopharm 2011-2022, by category
- Number of employees at Sinopharm 2011-2022
- Annual revenue of Sinopharm 2010-2022
Further Content: You might find this interesting as well
Statistics
- Celgene's revenue and net income 2006-2018
- M&A capacities - changes for the global pharma industry 2008-2015
- Medicinal market growth worldwide including rebates 2009-2018
- Expenditure worldwide on diabetes by market 2013-2018
- AstraZeneca's revenue from top product Pulmicort 2006-2022
- CVS Health's total assets 2005-2022
- Walgreens gross profit and net earnings in the U.S. 2005-2022
- Revenue of Sinopharm 2011-2022, by category
- Number of employees at Sinopharm 2011-2022
- Annual revenue of Sinopharm 2010-2022
IQVIA. (March 31, 2020). Changes in hospital outpatient prescriptions since COVID-19 outbreak in Busan and Gyeongnam in South Korea in 2020 [Graph]. In Statista. Retrieved September 23, 2023, from https://www.statista.com/statistics/1120095/south-korea-changes-in-outpatient-prescriptions-busan-gyeongnam/
IQVIA. "Changes in hospital outpatient prescriptions since COVID-19 outbreak in Busan and Gyeongnam in South Korea in 2020." Chart. March 31, 2020. Statista. Accessed September 23, 2023. https://www.statista.com/statistics/1120095/south-korea-changes-in-outpatient-prescriptions-busan-gyeongnam/
IQVIA. (2020). Changes in hospital outpatient prescriptions since COVID-19 outbreak in Busan and Gyeongnam in South Korea in 2020. Statista. Statista Inc.. Accessed: September 23, 2023. https://www.statista.com/statistics/1120095/south-korea-changes-in-outpatient-prescriptions-busan-gyeongnam/
IQVIA. "Changes in Hospital Outpatient Prescriptions since Covid-19 Outbreak in Busan and Gyeongnam in South Korea in 2020." Statista, Statista Inc., 31 Mar 2020, https://www.statista.com/statistics/1120095/south-korea-changes-in-outpatient-prescriptions-busan-gyeongnam/
IQVIA, Changes in hospital outpatient prescriptions since COVID-19 outbreak in Busan and Gyeongnam in South Korea in 2020 Statista, https://www.statista.com/statistics/1120095/south-korea-changes-in-outpatient-prescriptions-busan-gyeongnam/ (last visited September 23, 2023)
Changes in hospital outpatient prescriptions since COVID-19 outbreak in Busan and Gyeongnam in South Korea in 2020 [Graph], IQVIA, March 31, 2020. [Online]. Available: https://www.statista.com/statistics/1120095/south-korea-changes-in-outpatient-prescriptions-busan-gyeongnam/